Section Arrow
MOLN.NASDAQ
- Molecular Partners AG
Quotes are at least 15-min delayed:2026/02/19 19:18 EST
After Hours
Last
 5.24
+0.24 (+4.80%)
Bid
4.55
Ask
5.95
High 5.24 
Low 4.97 
Volume 22 
Regular Hours (Closed)
Last
 5
+0.27 (+5.71%)
Day High 
Prev. Close
4.73 
1-M High
4.75 
Volume 
5.73K 
Bid
4.55
Ask
5.95
Day Low
4.63 
Open
4.697 
1-M Low
3.965 
Market Cap 
176.90M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 4.63 
20-SMA 4.38 
50-SMA 4.33 
52-W High 5.1 
52-W Low 3.36 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.62/-1.27
Enterprise Value
178.12M
Balance Sheet
Book Value Per Share
3.32
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
4.97M
Operating Revenue Per Share
0.25
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TOVXTheriva Biologics Inc0.1967+0.0047+2.45%0.09PE
After Hours 0.1891 -0.0076 -3.86%
IBRXImmunityBio8.61+0.07+0.82%-- 
After Hours 8.5 -0.11 -1.28%
DRMADermata Therapeutics Inc1.93+0.65+50.78%0.08PE
After Hours 1.8099 -0.1201 -6.22%
QNCXQuince Therapeutics0.1622-0.0158-8.88%-- 
After Hours 0.163 +0.0008 +0.49%
LIMNLiminatus Pharma Inc0.2383-0.0066-2.69%-- 
After Hours 0.237 -0.0013 -0.55%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPintherapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.